Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid

Atypical lung carcinoid is a rare subtype of lung cancer, comprising 0.05% of all thoracic malignancies. In our case of a patient with metastatic atypical lung carcinoid, next-generation sequencing of the resected tumor identified a CCDC6-RET fusion. The patient initiated treatment with the oral selective RET inhibitor selpercatinib (LOXO-292) on a phase I/II study (NCT03157128) and had a partial response to therapy. Completing next-generation sequencing on rare tumors has become increasingly important in order to identify potential driver mutations and clinical trial opportunities for our patients.

Automated summary

The study showed that atypical lung carcinoid can be detected through next-generation sequencing to identify potential driver mutations and provide clinical trial opportunities for patients.